1182728-50-2 Usage
Description
1,3-dibromo-2-difluoromethoxy-benzene is an organic compound characterized by its bromine and fluorine atoms attached to a benzene ring, with a difluoromethoxy group at the 2nd position. 1,3-dibromo-2-difluoromethoxy-benzene is known for its chemical reactivity and structural properties, making it a versatile building block in the synthesis of various pharmaceuticals and other organic compounds.
Uses
Used in Pharmaceutical Industry:
1,3-dibromo-2-difluoromethoxy-benzene is used as a reactant for the preparation of chlorothiophene-isoxazoles, which are inhibitors of coagulation factors Xa and thrombin. These inhibitors play a crucial role in the development of anticoagulant drugs, which are essential for the treatment and prevention of blood clot-related disorders, such as deep vein thrombosis, pulmonary embolism, and stroke.
The application of 1,3-dibromo-2-difluoromethoxy-benzene in the pharmaceutical industry is primarily due to its ability to contribute to the synthesis of compounds with potential therapeutic effects. Its unique structure allows for further functionalization and modification, enabling the development of new drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1182728-50-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,2,7,2 and 8 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1182728-50:
(9*1)+(8*1)+(7*8)+(6*2)+(5*7)+(4*2)+(3*8)+(2*5)+(1*0)=162
162 % 10 = 2
So 1182728-50-2 is a valid CAS Registry Number.
1182728-50-2Relevant articles and documents
CHLOROTHIOPHENE-ISOXAZOLES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN
-
Page/Page column 51, (2009/10/18)
The present invention relates to compounds of the formula (I), wherein R1; R2; R3; R4; R5, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa and thrombin and can in general be applied in conditions in which an undesired activity of factor Xa and/or thrombin are present or for the cure or prevention of which an inhibition of factor Xa and thrombin are intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
